Westal (Mefenamic Acid) is commonly used to help with symptoms related to physical discomfort and conditions involving inflammatory or irritative processes. The medication is generally applied in scenarios where additional management of discomfort is required for symptoms associated with acute or episodic changes. It is considered relevant for easing symptoms related to physical discomfort, such as acute pain, as well as addressing symptoms related to systemic imbalance, specifically fever.

---

Key Therapeutic Applications

Westal is commonly used to help with acute, episodic manifestations including primary dysmenorrhea (painful periods), menorrhagia (heavy menstrual bleeding), and symptom clusters that may become intense or disruptive such as headaches, dental discomfort, and general musculoskeletal aches. It is applied across domains where additional symptomatic support is needed for joint discomfort associated with chronic inflammatory conditions. This use provides support that helps ease the overall symptom burden during symptomatic phases. The medication is relevant when supportive symptom management is appropriate, and may assist with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Symptom Management Context

Category	Typical Symptom Context
Primary Domain	Gynecological pain, general acute pain, fever
Symptom Scope	Cramping, tenderness, elevated body temperature
Benefit	Contributes to improved comfort during symptomatic periods
Usage Context	Episodic crises and acute symptom flares

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Westal

This section summarizes the official eligibility and non-eligibility information for Westal, strictly based on government-mandated regulatory documents like the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC). Information below reflects the limitations and restrictions defined by these authoritative sources.

Populations with Prohibited or Restricted Use

Classification	Population/Condition	Restriction Basis (Official Statement)
Contraindicated	Patients with known hypersensitivity or allergy to Westal or its components.	Official government labeling prohibits use due to risk of severe allergic reactions.
Not Recommended	Children under the age of 1 year.	Pediatric use is generally not recommended or established in this age group, requiring caution.
Not Recommended	Pregnant or breastfeeding women.	Use during pregnancy is often cautioned due to potential fetal risk shown in animal studies, and use while breastfeeding may require temporary cessation of nursing.
Special Consideration	Older adults (above 65 years).	Use requires caution, and dosage adjustment may be necessary due to increased sensitivity and risk of adverse effects.
Special Consideration	Renal or hepatic impairment.	Use requires medical consultation, as limited data may be available, and potential dose adjustment may be necessary depending on the degree of impairment.

All individuals should inform their healthcare provider of any pre-existing medical conditions, including depression, diabetes, epilepsy, and glaucoma, as these may require special consideration before beginning treatment with Westal.

Interactions with other medicines and products

The interaction profile for Westal (Mefenamic Acid) is based on patterns documented in regulatory sources and primarily involves pharmacokinetic and pharmacodynamic effects.

Formal Restrictions and Contraindications

Category	Documented Constraint
Other Systemic NSAIDs	Co-administration is formally contraindicated due to additive risk of serious gastrointestinal events.
CABG Surgery	Contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft surgery.

Clinically Significant Interactions

Oral Anticoagulants and SSRIs: Concomitant use with oral anticoagulants, such as Warfarin, or with SSRIs increases the documented risk of gastrointestinal and non-gastrointestinal bleeding. Mefenamic Acid has been shown to displace Warfarin from protein binding sites.

Blood Pressure and Water Pills: Mefenamic Acid may reduce the efficacy of Antihypertensives (ACE Inhibitors, ARBs) and Diuretics. This combination also increases the risk of renal function deterioration, particularly noted in the elderly and those with impaired renal function.

Altered Plasma Levels: Co-administration with Lithium and Methotrexate reduces their renal clearance, resulting in elevated plasma levels and potential toxicity, a pharmacokinetic effect documented in official labeling. Additionally, Mefenamic Acid is metabolized by CYP2C9, and reduced clearance can occur in poor metabolizers. Antacids containing Magnesium Hydroxide significantly increase the absorption rate of Mefenamic Acid.

Molecular Mechanism: Non-selective COX Inhibition

Westal's active component, Mefenamic Acid, exerts its pharmacodynamic action primarily through the competitive inhibition of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This non-selective interaction prevents the enzymes from converting arachidonic acid into prostanoids and their precursors. This is the foundational step that reduces the synthesis of key physiological mediators, notably Prostaglandin E2 (PGE2), within the Arachidonic Acid Cascade.

---

System-Level Physiological Modulation

Reduced peripheral PGE2 activity alters local vascular responses and lowers the activation threshold for nociceptors (pain-sensing neurons). Concurrently, the inhibition of PGE2 signaling centrally reverts the PGE2-driven elevation of the hypothalamic thermoregulatory set-point. The resulting physiological adjustment involves the reduction of excessive signaling within both the nociceptive and thermoregulatory pathways.

How Westal Is Used: Official Administration Guidelines

Westal (Mefenamic Acid) is administered exclusively through the oral route, typically available as 250 mg or 500 mg capsules and tablets. Official usage is strictly confined to short-term, acute relief and follows a standardized dosing protocol.

---

Standard Dosing Regimens

The approved dosing schedules vary slightly based on the condition being addressed, but they share a core pattern of starting with a single, higher dose, followed by lower maintenance doses taken as needed. For acute pain, the typical regimen begins with a 500 mg initial dose, followed by 250 mg every 6 hours as needed, and must not exceed 7 days of treatment. For Primary Dysmenorrhea (menstrual pain), the same initial and maintenance dosing applies, but the treatment duration is typically limited to 2 to 3 days, starting at the onset of symptoms.

---

Contextual Intake Conditions

To support proper intake and minimize gastrointestinal effects, the medicine should be taken with food, milk, or a full glass of water. The capsules or tablets must be swallowed whole and must not be crushed, broken, or chewed. Usage is limited to patients 14 years of age and older for these specific indications.

Classification	Detail
Administration Method Type	Oral
Frequency Pattern	Intermittent, As-Needed (PRN)
Use-Context Constraint	Shortest effective duration; maximum 7 days

Research Evidence for Primary Dysmenorrhea

Westal was studied for conditions characterized by fluctuating or episodic manifestations, specifically in research exploring painful menstrual periods (primary dysmenorrhea). The evidence base for this indication is primarily composed of Randomized Controlled Trials (RCTs). Research was applied in contexts involving adult women and female adolescents with moderate to severe primary dysmenorrhea. Studies monitored patient-reported outcomes describing perceived discomfort using established pain assessment scales and assessed the need for rescue pain medication.

Data show patterns related to how symptoms evolved in the observed populations during the study period. What remains uncertain is the durability of these patterns over a very long time, as long-term effects are not fully established, and follow-up durations were typically limited to only a few cycles of treatment.

---

Research Evidence for Heavy Menstrual Bleeding

Westal was evaluated in research exploring heavy menstrual bleeding (menorrhagia). Research for this condition includes controlled studies and systematic reviews. The primary focus of these studies was outcomes linked to inflammatory states, with researchers specifically examining the impact on the quantity of blood lost. Studies monitored the measured volume of menstrual blood loss (MBL) across cycles.

Trial data described patterns related to changes in the measured volume of menstrual blood loss. The evidence quality regarding findings for menorrhagia is assessed as moderate. This assessment is due to limitations like modest sample sizes in some key studies and variability in evidence quality across trials.

---

Research Evidence for Acute Pain and Fever

Research has explored outcomes related to physical discomfort, such as mild to moderate acute pain (e.g., post-dental surgery), primarily through single-dose, placebo-controlled RCTs. These studies monitored outcomes over very short observation periods (e.g., a few hours).

Westal was also studied for its antipyretic action (fever-lowering properties) in comparative randomized trials involving both adults and pediatric patients. These studies monitored measured changes in body temperature over a 24-hour period. Data for certain groups, particularly concerning the long-term effects in pediatric populations, remain insufficient or are derived from older studies.

Key Studies & References

1. Mefenamic Acid Oral Tablet: U.S. National Library of Medicine Drug Information
2. WHO Model List of Essential Medicines - Mefenamic Acid Entry
3. NICE Guideline: Heavy menstrual bleeding: assessment and management (referencing pharmacological options)

Common questions about Westal (FAQ)

---

Q: Is it common to experience [non-specific symptom, e.g., fatigue] while on Westal?

A: Official safety documents classify reported reactions by frequency. Symptoms like fatigue, sleepiness, or a feeling of loss of strength are mentioned as less common or infrequent reactions in the official safety listings. The full prescribing information can be consulted for a comprehensive list of documented adverse events.

---

Q: Is there a list of all potential side effects for Westal?

A: No single document provided to patients contains every possible reaction. Official product information provides lists of the most common and less common adverse reactions. The full, comprehensive list of documented side effects is reserved for the full prescribing information intended for healthcare professionals.

---

Q: Can Westal affect sleep patterns?

A: Regulatory safety information lists general effects like drowsiness and sedation as commonly reported. Additionally, other effects impacting the nervous system, such as experiencing trouble sleeping (insomnia), have been noted in the official adverse event reports.

---

Q: Does Westal interact with common pain relievers?

A: Official regulatory documents state that the co-administration of Westal with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is formally contraindicated. This restriction is in place due to the increased risk of serious side effects, particularly affecting the gastrointestinal tract.

---

Q: Does Westal have any known long-term risks beyond the common side effects?

A: According to official safety information, serious events such as gastrointestinal bleeding or certain cardiovascular thrombotic events (like heart attack or stroke) can occur at any time during treatment. These serious risks may not be preceded by warning symptoms.

---

Q: How long does it typically take to notice the effects of Westal?

A: Pharmacological data indicates that the active ingredient in Westal is rapidly absorbed into the body after it is taken by mouth.

---

Q: If I miss a dose of Westal, what does that mean for the overall schedule?

A: Official patient guidance states that if a dose is missed and remembered shortly after, guidance suggests taking it then. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. It is important that a double dose is not taken to compensate for a missed one.

---

Q: Can Westal be taken at any time of day?

A: Dosing instructions specify that the medicine is typically taken every 6 hours as needed for relief. Official documents note that the medicine is recommended to be taken with food, milk, or a full glass of water to help minimize stomach irritation.

---

Q: Is there a generic version of Westal available?

A: Yes, regulatory agencies have approved generic versions containing the active ingredient, Mefenamic Acid.

---

Q: Does Westal cause weight changes?

A: Official safety information lists weight changes (including unusual weight gain or loss) and appetite changes as adverse reactions that have been reported by patients taking this medicine.

---

Q: Can Westal be taken with vitamins or dietary supplements?

A: Official drug interaction information primarily focuses on prescription medicines. Regulatory documents generally advise that a healthcare provider be informed about all other supplements they take, including vitamins and herbs, before use.

---

Q: Does Westal interact with birth control pills?

A: Studies indicate that some types of oral contraceptives that contain the ingredient drospirenone may interact with Westal's active ingredient (Mefenamic Acid). This potential interaction may increase potassium levels. Consultation with a healthcare provider regarding the specific contraceptive method is advised.

---

Q: What happens if Westal is stopped suddenly?

A: Regulatory documents do not define specific withdrawal symptoms for this medicine. However, official safety precautions note that abruptly stopping certain medications, such as corticosteroids (often taken for inflammatory conditions), may lead to a worsening of the underlying disease.

---

Q: Does Westal affect the results of common lab tests?

A: Official prescribing information notes the potential for false-positive reactions when certain lab tests are used to check for the presence of bile in the urine. This specifically applies to the diazo tablet test method for urinary metabolites.

---

Q: How quickly does Westal leave the body?

A: Pharmacological data indicates the drug is eliminated from the body relatively quickly. The active ingredient has an elimination half-life of approximately two hours, which is the time it takes for half of the dose to leave the bloodstream.

---

Q: Does the efficacy of Westal change over time?

A: Research data examining the medicine's use for heavy menstrual bleeding (menorrhagia) indicated that the reduction in menstrual blood loss was maintained for up to 12 to 15 months in the women studied, suggesting sustained action over that period.

---

Q: Is it described as normal to feel no immediate change when starting Westal?

A: While the medicine is rapidly absorbed into the system, it is not a centrally acting drug designed to produce an immediate sensation or feeling. Therefore, not noticing an immediate change may be consistent with general expectations for this class of medicine.

---

Q: Does Westal interact with herbal teas or natural remedies?

A: Official interaction lists primarily focuses on prescription medicines. Regulatory documents generally advise that a healthcare provider be informed about all other supplements they take, including herbal teas and natural remedies, due to potential risks like increased bleeding when combined with an NSAID.

---

Q: Are there specific warning signs to look for when starting Westal?

A: Official safety documents advise watching for signs of serious side effects. These include indications such as black, tarry stools, vomiting that looks like coffee grounds, unusual swelling of the face, fingers, or legs, yellowing of the skin/eyes, or severe stomach pain.

How to Store and Dispose of Westal?

The official storage and disposal requirements for Westal (Mefenamic Acid) are intended to maintain product stability and ensure public safety, based on regulatory labeling.

---

Official Storage Requirements

• Environment: Store the medication at room temperature, strictly protected from excess heat, moisture, and direct light.
• Prohibited Conditions: The product must not be frozen and should not be stored in moist areas, such as a bathroom.
• Packaging: Keep Westal in the original container, ensuring the container is tightly closed at all times.

---

Official Disposal and Safety Rules

• Child Safety: It is mandatory to keep Westal out of the sight and reach of children.
• Disposal: Unused or expired medication must not be flushed down the toilet or poured into a drain.
• Guidance: Consult a healthcare professional or pharmacist for instructions on proper disposal according to local environmental regulations.